Next-generation RNA therapeutics through engineered endosomal escape
___
Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues, such as muscle, heart and the brain.
With successful PoCs in rodents and non-human primates, Sapreme is now building a pipeline of therapeutic applications to address high unmet needs in neuromuscular, cardiometabolic diseases and beyond.
Our lead program is designed as a best-in-class therapy for Duchenne muscular dystrophy, an incurable and fatal pediatric monogenic disease. In addition, we are pursuing strategic partnerships to co-develop products with select pharma/biotech companies.
Science
___
The problem: Less than 1% of next-generation therapeutics cross cellular barriers efficiently
Large molecules do not cross cell- or endosomal membranes efficiently. Therefore, intracellular target engagement is inefficient. This leads to limited new treatment options for patients, despite validated and promising disease targets. There is a high need for improved intracellular delivery of next-generation oligonucleotide therapeutics (siRNAs and ASOs).
Our solution: Harnessing the power of endosomal escape enhancers evolved in plant biology
Sapreme has selected a unique class of plant secondary metabolites (glycosylated triterpenoids) that specifically enhance delivery of large molecules to the cellular cytoplasm by mediating endosomal escape. Through advanced chemical modification of these natural compounds, Sapreme has developed a proprietary technology platform (SPT) with optimized medicinal properties. Our SPT platform selectively enhances receptor-targeted delivery to endosomes and enables pH-driven endosomal release of the therapeutic. Endosomal targeting and proprietary linker technology means that SPT remains inactive in circulation and has unprecedented endosomal escape potency and tolerability.
Team
___
Executive Management Team
Board of Directors
Scientific Advisory Board
News & Events
___
Press Releases
- Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026Utrecht, Netherlands – 14 October 2026: Sapreme Therapeutics (“Sapreme” or the “Company”), a biotechnology company developing next-generation RNA therapeutics for patients with genetically driven diseases, today announces the oral presentation of new preclinical data from its lead Duchenne muscular dystrophy (DMD) programme, SPM-2551, at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place in Denver, Colorado, US. A selection of these data was also presented recently by Sapreme’s Scientific Advisory Board member, Professor Annemieke Aartsma-Rus, a leading… Read more: Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
- Sapreme Development B.V. to become Sapreme Therapeutics B.V.As our company continues to evolve, we’re excited to announce that effective June 1st, 2026, Sapreme Development B.V. will become Sapreme Therapeutics B.V. Over the past years, our focus has progressed from platform technology toward the development of a growing portfolio of therapeutic programs. Our new name reflects that evolution and our future as a therapeutics-focused biotech company. This is a name change only, and we look forward to continuing this journey together with our partners, collaborators, and broader network.
Upcoming Events
Meeting: 22nd Annual Meeting of the Oligonucleotide Therapeutics Society, October 11-14, Denver, USA
Title: Toward the Clinic: Targeted Oligonucleotide Conjugates with Built-in Endosomal Escape Enable Durable Pharmacology at Picomolar Tissue Exposure
Speaker: Miriam Bujny, Chief Development Officer, Sapreme Therapeutics
Date: Wednesday, October 14, 9:55-10:10, Session X – Chemistry, Mechanism and Delivery (II)
https://www.2026oligomeeting.com/meeting-agenda
About Sapreme:
Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues.
Careers
___
Open applications welcome
If you are a talented individual interested in contributing to our mission, please send your resume to careers@sapreme.com
Contact
___
Telephone
+31 30 760 09 76
(Main office Desk)
Address
Yalelaan 62
LSI, Utrecht Science Park
3584 CM Utrecht
The Netherlands